
ãã«ã³ã¬ãã·ãŒã§å€±ãããã·ã°ãã«ãå埩ãFDAãåã®ãªã¬ãã·ã³æšçè¬ãæ¿èª
ãã«ã³ã¬ãã·ãŒ1åã®æ£è ã«ãšã£ãŠãæ²»çã¯é·ãéãã€ãã¯ãã®å¯ãéãã ã£ããæ¥äžã®ç æ°ãæããäžæ¢ç¥çµåºæ¿è¬ãã«ã¿ãã¬ãã·ãŒ(æ åè±åçºäœ)ãåããããªãã·é žãããªãŠã ãå¹»èŠãç¡ç 麻çºã«çšããæãã€è¬ãããããåé¡ã®æ ¹æ¬ã«ã¯è§ŠããŠããªãã£ãã2026幎8æ5æ¥ããã®ç¶æ³ãå€ãã£ããç±³é£åå»è¬åå±(FDA)ã¯ãTakedaã®çµå£è¬Orzeyful(oveporexton)ããã«ã³ã¬ãã·ãŒ1åã®æäººæ£è åãã«æ¿èªãããFDAã¯ãããããã®çŸæ£å šäœã察象ãšããŠæ¿èªãããåã®æ²»çè¬ã§ããããã®äœçšæ©åºãããã®ç æ°ã§å€±ããããªã¬ãã·ã³ã·ã°ãã«ã®çŽæ¥çãªå埩ã§ããåã®è¬å€ã ãšããŠããã ãã®çŸæ£ã¯ããã2000人ã«1人ã眹æ£ããçæ¶¯ã«ããã£ãŠç¶ãããã°ãã°äœå¹Žã蚺æãããªãããã®ç¹åŸŽçãªç æ ã¯ããªã¬ãã·ã³ãç£çããç¥çµçްèã®åªå€±ã§ããããªã¬ãã·ã³ã¯1998幎ã«çºèŠãããååŠäŒéç©è³ªã§ãèŠéãç¡ç ãçç·åŒµã調ç¯ããããã®ã·ã°ãã«ã倱ããããšãèŠéãä¿ã€ããšãçµ¶ãéãªãéããšãªããç¡ç ãšèŠéã®å¢çããããŸãã«ãªãããã®çµæãæç¶çãªæ¥äžã®ç æ°ãç¬ããªã©ã®åŒ·ãææ ã«ãã£ãŠçèãäžæçã«éº»çºããã«ã¿ãã¬ãã·ãŒãç¡ç 麻çºãç¡ç ã®å¢ç®ã«çŸããå¹»èŠããããŠåæãããå€éç¡ç ãçããããããã®çç¶ã¯ãé£äºãæ©è¡ãé転ã®åŠšãã«ãªãåŸããFDAãææããããã«ãä»åã®æ¿èªä»¥åã«ã¯ããã®çŸæ£ãåäžã®ç¶æ ãšããŠæ¿èªãããè¬å€ã¯äžåºŠããªãããªã¬ãã·ã³ç³»ã«äœçšããè¬å€ãååšããªãã£ããåŸæ¥ã®è¬å€ã¯åå ããäžæµã§äœçšãããäžæ¢ç¥çµåºæ¿è¬ãã¢ããã£ãã«ããããªãµã³ããªã©ã®èŠéä¿é²è¬ã¯ç æ°ãæãããªãã·é žãããªãŠã ã¯ã«ã¿ãã¬ãã·ãŒãšå€éã®ç¡ç é害ãåãããæãã€è¬ã¯REMé¢é£çç¶ã匱ããã Orzeyfulã¯ç°ãªãã¢ãããŒããåããããã¯æ°ããã¯ã©ã¹ã®å»è¬åã§ããçµå£OX2Rã¢ãŽãã¹ãã«å±ããè³èªèº«ã®ãªã¬ãã·ã³ãæ¬æ¥äœçšãããã¹ãå容äœãã®ãã®ã掻æ§åããŠãçç¶ã®åœ±é¿ã管çããã®ã§ã¯ãªãã倱ãããã·ã°ãã«ãåæ§ç¯ãããé å€ãšããŠ1æ¥2åæçšããã ãšããã³ã¹ã¯ãFirstLightãšRadiantLight(NCT06470828ããã³NCT06505031)ãšãã2ã€ã®ã©ã³ãã åäºéç²æ€ãã©ã»ãå¯Ÿç §12é±é詊éšããåŸãããã䞡詊éšã«ã¯19ã«åœãã273äººã®æäººãç»é²ãããã2mgã®çšéã§ããã®è¬å€ã¯ã人ãã©ãã ãé·ãèŠéãç¶æã§ãããã客芳çã«ç€ºãMaintenance of Wakefulness Test(èŠéç¶æãã¹ã)ã§ãã©ã»ããäžåããæ¥äžã®ç æ°ãå€§å¹ ã«æžããããã«ã¿ãã¬ãã·ãŒçºäœã¯ææã«æžå°ããç¡ç 麻çºãå¹»èŠãå€éç¡ç ã®åæãå«ãæ®ãã®çç¶ã®å šåã«ããã£ãŠæ£è ã¯æ¹åã瀺ããã詊éšã§ã¯ãŸããæ¥åžžçæŽ»æ©èœãšèªç¥æ©èœã®æ¹åãå¹»èŠãšç¡ç 麻çºãšããœãŒãã®æžå°ããããŠããå¥åº·çãªãã¿ãŒã³ãžãšåããREMæ§é ã®å€åãèšé²ãããã詊éšãå®äºãã人ã®ãã¡95%è¶ ãé·æå»¶é·è©Šéšãžã®ç¶ç¶ãéžæããå¯äœçšã«ããæ²»çäžæ¢ã¯ããå°æ°ã ã£ãã å®å šæ§ãããã¡ã€ã«ã¯ãèŠéç³»ãæŽ»æ§åããããšã§äºæž¬ãããå 容ãšäžèŽããŠãããå¯äœçšã¯ãèŠéãé«ããè¬å€ã«å žåçã«èŠãããé åã«éäžãããããªãã¡ç¡ç é害ãå°¿æåè¿«æã䌎ãé »å°¿ããããŠåŸæ¶²åæ³éå€ã§ããã匷åãªCYP3Aé»å®³è¬ãšã®äœµçšã¯çŠå¿ã§ãããæ£è ã¯æçšäžã®ãã¹ãŠã®è¬å€ãæ åœå»ã«ç³åããããæ±ããããŠããã18æ³æªæºã§ã®å®å šæ§ãšæå¹æ§ã¯ç¢ºç«ãããŠããªãã Orzeyfulãæ£è ã®ããšã«å±ããŸã§ã«ã¯ããŸã ããã€ãã®æ®µéãæ®ã£ãŠããããã®è¬å€ã¯ãé節ãªçŸæ£ã«å¯Ÿããå€§å¹ ãªæ¹åã瀺ãåæãšããã³ã¹ãåæ ããFDAã®ç»æçæ²»çè¬æå®(Breakthrough Therapy designation)ãšåªå 審æ»ãåãããFDAã¯ãŸãããã®è¬å€ãèŠå¶ç©è³ªæ³(Controlled Substances Act)ã«åºã¥ãã¹ã±ãžã¥ãŒã«æå®ã®å¯Ÿè±¡ãšããããå§åããããã®ããåæ³çãªè²©å£²ã¯ã90æ¥ä»¥å ãšèŠèŸŒãŸããç±³åœéº»è¬åç· å±(DEA)ã®ã¹ã±ãžã¥ãŒã«æ±ºå®ãåŸ ã€å¿ èŠããããTakedaã¯ããã®åŸãã®è¬å€ã¯å°éè¬å±ãéããŠç±³åœã®å»çåŸäºè ãšãã«ã³ã¬ãã·ãŒ1åã®æäººæ£è ã«æäŸããããšè¿°ã¹ãã äœå幎ã«ãããã£ãŠãã«ã³ã¬ãã·ãŒ1åãçç¶ããšã«æ²»çããŠããåéã«ãšã£ãŠãä»åã®æ¿èªã¯æ¹åæ§ã®è»¢æã瀺ããOrzeyfulã¯ããã®çŸæ£ãæ®ãçç¶ã§ã¯ãªãããã®ååã¬ãã«ã®äžæ žã§ãã倱ããããªã¬ãã·ã³ã·ã°ãã«ã«åã蟌ãåã®æ²»çè¬ãšããŠãä»ã«é¡ãèŠãªãããã®ã·ã°ãã«ã®å埩ããã®çŸæ£ãæ±ãã人ã ã®æ¥åžžç掻ãå®è³ªçã«å€ãåŸããã©ããã¯ãããããèšåºã®çŸå Žã§ãåŠæ¹ç®1æããšã«è©Šãããããšã«ãªãã é å èš³ Source American Academy of Sleep Medicine, “FDA Approves Orzeyful for Narcolepsy Type 1 in Adults,” Aug. 6, 2026, https://aasm.org U.S. Food and Drug Administration, “FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms,” Aug. [âŠ]










